previou
report
suggest
type
type
ii
interferon
cooper
inhibit
viru
replic
eg
hcv
sarscov
find
molecular
mechan
underli
phenomenon
analyz
transcript
profil
stimul
cell
found
transcript
subset
ifn
stimul
gene
isg
includ
bclg
trail
enhanc
present
promot
analysi
bclg
reveal
requir
process
enhanc
complex
format
observ
interferon
cotreat
group
gel
shift
analysi
furthermor
activ
found
gener
requir
cluster
isg
tyrosin
phosphoryl
elev
ifn
combin
treatment
howev
hypertransactiv
ga
isr
observ
conclus
hyperactiv
elev
dimer
format
may
two
gener
switch
contribut
much
robust
antivir
symphoni
viru
replic
type
type
ii
ifn
coadminist
hyperactiv
contribut
enhanc
interferon
stimul
gene
isg
express
interferon
cotreat
human
hepatoma
cell
xiaonan
zhang
jiangxia
liu
yunwen
hu
b
hui
chen
zhenghong
yuan
b
interferon
ifn
pleiotrop
cytokin
mediat
antivir
antiprolif
antitumor
immunomodulatori
activ
interferon
categor
two
major
class
ie
type
predominantli
type
ii
interferon
two
class
interferon
bind
differ
pair
receptor
cell
membran
overlap
rout
signal
downstream
type
interferon
preferenti
trigger
format
isg
factor
complex
compos
phosphoryl
togeth
bind
ifnstimul
respons
element
isr
within
promot
certain
isg
type
ii
interferon
induc
tyrosin
phosphoryl
result
format
homodim
bind
activ
site
ga
element
addit
type
ii
interferon
potent
induc
express
shown
stimul
variou
gene
antivir
antiprolif
immunomodulatori
activ
human
type
ifn
long
recogn
clinic
antivir
immunomodulatori
effect
wide
use
treat
hepat
b
hepat
c
viru
infect
although
limit
percentag
sustain
respons
similar
potent
antivir
activ
mani
vitro
vivo
viru
replic
model
howev
applic
clinic
viral
infect
turn
unsuccess
toxic
also
frequent
observ
interestingli
recent
year
grow
bodi
evid
shown
type
type
ii
ifn
coadminist
replic
mani
virus
inhibit
even
strikingli
sainz
et
al
demonstr
seri
articl
type
type
ii
ifn
could
synerg
inhibit
herp
simplex
viru
type
human
cytomegaloviru
sever
acut
respiratori
syndrom
coronaviru
sarscov
replic
fuchizaki
et
al
also
report
combin
mous
prolong
surviv
period
mice
infect
mous
hepat
viru
type
consist
lower
level
heptocellular
necrosi
serum
alanin
aminotransferas
alt
decreas
titer
viru
load
also
case
vitro
hcv
replicon
system
coadminist
furthermor
prime
boost
protocol
clinic
trial
success
invok
respons
hcv
six
nineteen
patient
fail
previou
monotherapi
light
experiment
clinic
evid
time
probe
molecular
process
underli
phenomena
small
cluster
gene
identifi
whose
express
enhanc
cotreat
includ
bclg
famili
protein
g
xlink
inhibitor
apoptosi
associ
trail
tnfrelat
apoptosi
induc
ligand
transport
subsequ
promot
analysi
bclg
show
interferon
regulatori
factor
signal
transduc
activ
transcript
essenti
full
enhanc
gene
express
moreov
enhanc
complex
format
also
observ
emsa
analysi
knock
express
specif
small
interf
rna
sirna
suppress
enhanc
bclg
also
member
cluster
suggest
gener
role
process
tyrosin
phosphoryl
enhanc
activ
ga
ifngammaactiv
site
isr
interferonstimul
respons
element
observ
taken
togeth
postul
hyperactiv
elev
dimer
format
associ
enhanc
express
subset
interferon
stimul
gene
isg
may
lead
even
greater
antivir
activ
cell
maintain
dmem
supplement
fetal
calf
serum
mmolml
lglutamin
penicillin
streptomycin
gibco
brl
plasmid
dna
transfect
use
fugen
roch
sirna
transfect
oligofectamin
invitrogen
antibodi
obtain
santa
cruz
antibodi
tyr
cell
signal
bclg
antibodi
obtain
orbigen
antibodi
sigma
human
purchas
calbiochem
peprotech
respect
total
rna
cell
variou
stimul
extract
use
trizol
reagent
gibco
brl
follow
min
dnasei
digest
remain
genom
dna
pure
rna
revers
transcrib
use
superscript
ii
invitrogen
random
hexam
primer
accord
manufactur
instruct
realtim
pcr
icyl
biorad
perform
instruct
icycl
resourc
guid
briefli
reaction
carri
volum
contain
cdna
templat
nm
forward
revers
primer
sybr
greeni
unit
hotstart
extaq
takara
linear
plasmid
contain
bp
gapdh
cdna
quantifi
dilut
standard
cycl
number
logarithm
linear
phase
plot
logarithm
concentr
templat
dna
primer
use
list
tabl
upper
panel
dual
luciferas
assay
perform
accord
manufactur
protocol
promega
cell
extract
use
sd
sampl
buffer
mm
trishcl
ph
wv
sd
glycerol
mm
dtt
wv
bromophenol
blue
equal
amount
protein
extract
load
sdspage
gel
electrophoresi
protein
transfer
onto
nitrocellulos
membran
perkin
elmer
transfer
buffer
mm
tri
mm
glycin
methanol
ph
membran
incub
variou
antibodi
follow
addit
horseradish
peroxidaseconjug
goat
antirabbit
goat
antimous
igg
santa
cruz
protein
visual
ecl
western
blot
system
western
perkin
elmer
bclg
promot
amplifi
human
genom
dna
healthi
donor
pcr
insert
promega
subsequ
truncat
delet
mutant
done
subclon
fusion
pcr
sequenc
primer
use
clone
tabl
primer
dna
probe
sirna
use
studi
sequenc
nuclear
extract
prepar
use
nuclear
extract
kit
activ
motif
p
label
dna
probe
bind
reaction
done
use
gel
shift
kit
promega
accord
instruct
briefli
nuclear
extract
incub
room
temperatur
p
label
irf
bclg
promot
bind
buffer
sequenc
probe
list
tabl
middl
panel
antibodi
cold
irf
mutant
irf
ad
min
p
label
probe
includ
supershift
competit
reaction
min
incub
probe
room
temperatur
complex
load
polyacrylamid
gel
tbe
subject
electrophoresi
gel
dri
analyz
use
phosphorimag
instrument
fuji
medic
system
sequenc
sirna
list
tabl
lower
panel
sirna
synthes
genechem
co
ltd
transfect
sirna
perform
describ
user
manual
invitrogen
microarray
analysi
class
gene
shown
hyperactiv
coadminist
unpublish
data
subsequ
realtim
pcr
confirm
least
transcript
bclg
long
form
trail
inde
enhanc
tabl
bclg
novel
member
famili
homolog
domain
proapoptot
overexpress
bclg
encod
two
protein
altern
splice
long
form
bclg
express
wide
variou
tissu
wherea
short
form
restrict
testi
sinc
gene
report
isg
time
analysi
select
prototyp
examin
clone
region
bclg
promot
insert
silico
analysi
region
identifi
ifngammaactiv
site
ga
interferon
regulatori
factor
element
irf
close
togeth
http
mbscbrcjpresearchdbtfsearch
html
camp
respons
element
cre
also
identifi
downstream
fig
express
fulllength
report
construct
show
clear
synerg
cotreat
fig
activ
total
depend
upon
tyrosin
phosphoryl
overexpress
mutant
made
unrespons
interferon
cotreat
fig
truncat
proxim
sequenc
allevi
increas
synerg
ga
element
delet
fig
howev
could
still
detect
three
fold
induct
cotreat
suggest
anoth
factor
involv
region
intern
delet
downstream
sequenc
alter
express
pattern
fig
delet
cre
also
effect
therefor
focus
ga
irf
element
delet
ga
irf
significantli
alter
respons
treatment
doubl
delet
led
complet
unrespons
either
cytokin
fig
sinc
ga
irf
close
bp
chang
interven
sequenc
two
random
sequenc
howev
signific
differ
observ
fig
thu
conclud
irf
ga
import
synergist
activ
bclg
transcript
sinc
previou
result
fig
demonstr
indispens
role
irf
sought
find
irf
bind
element
neither
seem
particip
bclg
transcript
cotransfect
domin
neg
form
significantli
alter
express
pattern
data
shown
howev
coexpress
basal
express
greatli
increas
besid
dose
depend
phenomenon
also
observ
fig
gel
shift
analysi
suggest
overexpress
could
bind
irf
bclg
promot
arrow
addit
specif
antibodi
effect
elimin
complex
fig
investig
whether
inde
respons
synergist
activ
bclg
physiolog
set
cotransfect
treat
cell
fig
significantli
alter
report
express
wherea
could
slightli
increas
luciferas
activ
support
idea
factor
eg
may
involv
activ
bclg
transcript
treatment
coexpress
also
abolish
enhanc
report
express
ifn
cotreat
confirm
critic
role
process
verifi
nuclear
factor
associ
irf
perform
emsa
analysi
use
irf
correspond
bclg
promot
probe
shown
fig
cotreat
led
enhanc
band
shift
arrow
compar
treatment
addit
specif
antibodi
supershift
complex
arrow
b
addit
antibodi
effect
shift
band
effect
inhibit
ad
fold
cold
probe
mutant
oligo
western
blot
analysi
bclg
confirm
synergist
effect
although
slightli
differ
compar
transcript
level
fig
ad
mark
decreas
bclg
observ
possibl
bclg
degrad
activ
treatment
sinc
bclg
found
link
mnsf
monoclon
nonspecif
suppressor
factor
ubiquitin
homolog
protein
although
treatment
result
signific
increas
bclg
protein
cotreat
clearli
upregul
express
fig
differ
induct
profil
protein
mrna
level
presum
caus
halflif
bclg
possibl
differ
degrad
effici
variou
stimul
context
level
minim
express
observ
untreat
treat
cell
treatment
obviou
induct
seen
describ
previou
report
contrast
enhanc
bind
activ
emsa
experi
signific
increas
observ
cotreat
still
well
understood
level
remain
constant
treatment
group
elucid
role
alter
transcript
profil
synergist
antivir
activ
ifn
cotreat
synthet
sirna
direct
use
abrog
activ
induct
treatment
significantli
inhibit
sirna
transfect
fig
express
unchang
effect
sirna
synergist
enhanc
gene
assess
quantit
rtpcr
expect
enhanc
mrna
level
bclg
significantli
reduc
gapdh
versu
treatment
p
similar
express
profil
chang
observ
versu
p
versu
p
trail
versu
p
fig
silico
transcript
factor
bind
site
analysi
promot
trail
also
identifi
put
bind
site
fig
ascertain
specif
sirna
express
mxa
wellknown
independ
isg
also
quantifi
inde
transfect
sirna
affect
mrna
level
mxa
versu
p
ifn
combin
treatment
fig
data
strongli
support
idea
activ
gener
switch
lead
enhanc
gene
express
subset
isg
interestingli
previou
report
shown
requir
trail
induct
retino
acid
ga
irf
arrang
promot
similar
bclg
indic
element
crucial
induct
treatment
sinc
evid
show
prime
could
amplifi
induc
activ
human
macrophag
check
phosphoryl
cell
min
treatment
tyrosin
phosphoryl
could
detect
either
monotreat
although
differ
intens
accord
publish
data
hyperphosphoryl
readili
observ
cotreat
fig
play
pivot
role
transcript
activ
signal
monitor
induct
downstream
interferonstimul
respons
element
isr
ga
report
express
treatment
led
lag
isr
activ
compar
howev
combin
cytokin
enhanc
isr
activ
fig
suggest
interferon
stimul
gene
factor
complex
format
elev
ga
assay
cotreat
result
two
fold
activ
compar
treatment
suggest
increas
homodim
format
fig
basic
research
clinic
trial
repeatedli
demonstr
type
type
ii
ifn
interdepend
signal
shown
depend
receptor
compon
knockout
mice
model
recent
clinic
trial
use
ifnalfacon
treat
hcv
patient
unrespons
pegifn
ribavirin
treatment
shown
sustain
virolog
respons
remark
higher
prolong
standard
treatment
underli
mechan
believ
two
fold
innat
antivir
effect
may
enhanc
addit
type
ii
ifn
adapt
immun
retun
respons
thu
facilit
viru
erad
specif
ctl
cytotox
lymphocyt
studi
focus
immedi
antivir
activ
ifn
combin
treatment
host
celllin
support
hcv
replic
cluster
gene
bclg
trail
shown
transcript
enhanc
cotreat
subsequ
promot
analysi
bclg
reveal
crucial
regul
interestingli
similar
ga
irf
arrang
promot
phox
also
document
allow
rapid
induct
express
treatment
cell
nevertheless
due
strict
tissu
specif
myeloid
express
pattern
phox
could
detect
cell
unpublish
data
although
increas
phosphoryl
demonstr
found
ga
isr
mediat
transcript
enhanc
suggest
homo
dimer
rather
format
prefer
induc
dramat
upregul
upon
viru
infect
ifn
stimul
observ
suggest
function
regul
cellular
respons
ifn
affect
set
isg
interestingli
studi
dna
bind
activ
shown
enhanc
cotreat
analysi
support
gener
role
regul
cluster
gene
inde
basal
express
level
found
significantli
lower
cell
harbor
replicon
indic
could
greatli
hamper
replic
hcv
variant
clone
hcv
replicon
could
block
dna
bind
activ
suppress
express
depend
isg
intriguingli
base
previou
report
bclg
trail
thought
associ
apoptosi
bclg
conjug
mnsf
kda
protein
ident
ubiquitin
posttransl
modif
bclg
might
implic
tcell
activ
preliminari
studi
bclg
long
form
show
signific
proapoptot
effect
direct
antihcv
activ
least
cell
data
shown
given
molecular
function
still
well
defin
bclg
merit
investig
antivir
proapoptot
activ
trail
member
tnf
famili
select
apoptosi
activ
cancer
cell
normal
cell
larg
insensit
mice
display
overt
phenotyp
increas
suscept
tumor
initi
metastasi
xlink
inhibitor
apoptosi
associ
shown
associ
xiap
express
trigger
redistribut
xiap
cytosol
nucleu
antagon
xiap
activ
protein
induct
observ
predominantli
melanoma
cell
line
sensit
proapoptot
effect
cell
constitut
express
sensit
trail
induc
apoptosi
similar
express
kinet
cooper
proapoptot
activ
indic
cluster
enhanc
gene
fine
regul
fulfil
specif
task
eg
immunosurveil
cancer
cell
report
howev
role
control
viru
replic
exclud
inde
propos
novel
antivir
function
type
ifn
select
induct
apoptosi
viral
infect
cell
hand
virus
also
encod
variou
gene
antagon
proapoptot
signal
exampl
protein
hcv
well
known
antiapoptot
activ
although
exact
mechan
still
controversi
ebv
epsteinbarr
viru
encod
poli
rna
eber
exhibit
strike
resist
induc
apoptosi
burkitt
lymphoma
cell
line
overal
data
provid
evid
hyperinduct
subclass
isg
mainli
control
hyperactiv
elev
dimer
format
coadminist
although
four
enhanc
gene
unequivoc
identifi
studi
believ
mani
gene
cluster
yet
found
investig
need
expand
cluster
elucid
function
member
may
play
import
role
innat
antivir
activ
interferon
also
awar
fact
enhanc
transactiv
capac
shown
emsa
correl
well
protein
express
level
intens
analysi
done
elucid
mechan
underli
phenomenon
